The NHMRC Vaping Review: When “Evidence-Based” Isn’t Neutral

The Australian government says this is just a routine “update.” It isn’t. It’s a reset of the narrative, one that risks entrenching the same institutional blind spots that have already shaped Australia’s uniquely hostile stance on vaping.

At the centre of this process is the National Health and Medical Research Council, an institution whose statements carry enormous weight. What it publishes doesn’t just inform, it legitimises. It becomes the reference point for regulators, politicians, media outlets, and public health campaigns. That influence comes with responsibility, and that is exactly why this update deserves far more scrutiny than it is currently receiving.
Because this process is not starting from neutral ground. It is building on a foundation that has already been challenged, not just by fringe voices, but by established international researchers who have raised serious concerns about the integrity and balance of previous NHMRC conclusions.

The 2022 statement, the one now being revised, was criticised for overstating harms, downplaying benefits, and applying standards to vaping that are rarely applied to other public health interventions. That critique didn’t emerge from industry talking points. It came from academics pointing out methodological inconsistencies, selective citation practices, and a failure to properly contextualise risk.
And yet, instead of confronting those criticisms directly, the new process appears to quietly move forward as if they never existed.

The updated statement, scheduled for completion in 2027, will be guided by the NHMRC Electronic Cigarettes Advisory Committee. On paper, this sounds reassuring: a panel of experts reviewing the evidence across toxicology, epidemiology, addiction science, and public health. But expertise alone is not the issue. The real question is whether the committee represents a genuine diversity of scientific perspectives, or whether it reflects the same entrenched consensus that has defined Australia’s approach to vaping for years.

And this is where the issue of membership becomes impossible to ignore.
Look at the composition of advisory bodies in Australia’s tobacco control space more broadly, and a pattern emerges. The same networks of academics, public health advocates, and institutional voices appear repeatedly across committees, working groups, and policy consultations. Many are affiliated, directly or indirectly, with organisations such as the Cancer Council Australia, long recognised for its hardline stance against vaping, or have contributed to influential reports like Generation Vape, which has itself been criticised for selective framing of youth data.
This is not about questioning individual integrity. It is about recognising structural bias.

When committee membership is drawn from a relatively narrow professional ecosystem, one that has already taken a clear position on vaping, the range of acceptable conclusions narrows before the review even begins. Dissenting perspectives are not necessarily excluded outright, but they are often underrepresented, outnumbered, or framed as outliers rather than legitimate scientific positions.

That matters because consensus in this context can become self-reinforcing.
If everyone in the room fundamentally agrees on the risks, the framing of the problem, and the policy direction, then the process becomes less about interrogating evidence and more about refining a shared narrative. The appearance of balance is maintained, but the substance is constrained.

This is particularly evident in how “conflicts of interest” are approached. Industry-linked research is rightly scrutinised, but in Australia it is often dismissed wholesale, regardless of methodological quality. Meanwhile, the potential for institutional bias within tobacco control organisations, where careers, funding, and public positions are tied to a specific narrative, is rarely subjected to the same level of critical examination.
It is a double standard that shapes outcomes.

The language of the review reinforces this dynamic. The focus areas include harms, youth uptake, long-term uncertainty, and bias. All legitimate topics. All important. But notice the framing. Risk is foregrounded, uncertainty is emphasised, and bias is assumed, particularly when it comes to research that might support harm reduction.
What is missing is an equally strong, explicit commitment to evaluating substitution effects. Not hypothetical risks, but real-world outcomes. Not whether vaping is safe in isolation, but whether it reduces harm compared to smoking.

That distinction is everything.

Because public health does not operate in a vacuum. Smokers are not choosing between vaping and clean air. They are choosing between vaping and cigarettes. Ignoring that comparative reality distorts the entire analysis.
This is not a theoretical concern. It has already played out in Australia’s policy settings, where vaping has been treated primarily as a problem to be controlled rather than a tool to be evaluated. The result is a regulatory environment that is among the strictest in the developed world, despite growing international evidence supporting harm reduction approaches.

Then there is the issue of evidence gaps, particularly around long-term harms. This is perhaps the most frequently cited justification for caution, and on its face, it is reasonable. Vaping has not existed for decades, so long-term data is inherently limited.
But the way this uncertainty is used in policy discussions is deeply inconsistent.
Uncertainty around long-term harms becomes a reason to restrict vaping. Yet the well-established, immediate harms of smoking, responsible for immense disease burden and mortality, are often treated as a background constant rather than the central comparator.

In effect, the absence of perfect knowledge about vaping is given more weight than the presence of overwhelming knowledge about smoking.
That is not a precaution. That is a distortion.

Because precaution, properly applied, should consider the relative risk. It should ask what happens if smokers are denied access to less harmful alternatives. It should ask what happens if policy settings push them back toward cigarettes, or prevent them from switching in the first place.

Those questions rarely sit at the centre of Australian discussions, and there is little indication that this new NHMRC process will change that.
Meanwhile, the international landscape tells a very different story. In New Zealand and the United Kingdom, vaping has been integrated into smoking cessation strategies. Public health authorities there have not ignored risks, but they have weighed them against benefits. They have treated harm reduction as a legitimate component of tobacco control, not a threat to it.

The outcomes speak for themselves: accelerated declines in smoking rates, particularly among younger populations transitioning away from combustible tobacco.
Australia, by contrast, continues to position itself as an outlier, and this NHMRC update risks reinforcing that position under the banner of scientific rigour.
There is also a broader cultural issue at play. Australia’s public health establishment has, over time, developed a strong institutional consensus on vaping, one that is rarely challenged from within. Dissenting voices are often framed as controversial, even when they are grounded in mainstream international evidence.

That environment does not encourage open scientific debate. It discourages it.
And when debate is constrained, so too is the quality of the conclusions that emerge.
To be clear, the NHMRC process will follow formal steps. There will be systematic reviews, stakeholder consultations, drafts, revisions, and final recommendations. It will look, from the outside, like a robust and transparent exercise.

But process alone does not guarantee objectivity.

If the same assumptions underpin the review, if harm is consistently prioritised over relative benefit, if uncertainty is selectively amplified, and if certain forms of evidence are treated with default scepticism, then the outcome is not genuinely open-ended.
It is predetermined within a narrow range.

And that is the core concern.

Because this is not just about a document. It is about the direction of public health policy in Australia for years to come. It is about whether harm reduction is given a fair hearing or systematically sidelined. It is about whether smokers are presented with a full, honest picture of their options, or a filtered version shaped by institutional preferences.

The NHMRC calls this an update. But unless something fundamentally changes, unless the process genuinely engages with criticism, embraces comparative risk, and allows for real diversity of scientific thought, it will not function as a course correction.

It will function as reinforcement.

Reinforcement of a narrative that has already been widely challenged.
Reinforcement of a policy framework that remains out of step with much of the developed world.

And most importantly, reinforcement of a system where the debate that matters most, how to reduce the harms of smoking in the real world, continues to be constrained by the very institutions tasked with addressing it.